Pakistan

Section divider

We’ve been working to protect the health of women and babies since 1997.

  • More than 1.7 million antenatal care visits were conducted by skilled providers at Jhpiego-supported health care facilities, and over 390,000 babies were delivered with the assistance of a skilled birth attendant able to recognize and respond to medical complications.
  • More than 149,000 postpartum/postabortion women initiated a modern contraceptive method at Jhpiego-supported health care facilities.
  • Jhpiego’s advocacy resulted in postpartum family planning strategies being implemented across four provinces, as well as chlorhexidine being included in the country’s approved essential medicines list and misoprostol being added to the essential drug list for Punjab Province (chlorhexidine and misoprostol are both lifesaving medicines, the former to prevent umbilical cord infection and the latter to prevent postpartum bleeding).
  • Improved quality of care through post-training follow-up and supportive supervision, coupled with an expanded method mix, led to more than 123,000 new users of family planning.

Our Work in Pakistan

Funded by the U.S. Centers for Disease Control and Prevention (CDC), this five-year project builds upon activities funded by CDC to support Global Health Security through implementation of programs and activities that focus on protecting and improving health globally through partnerships with Ministries of Health and other institutions. With an initial emphasis on addressing the COVID-19 pandemic, the project is supporting countries—including Pakistan—as well regional work in West Africa and South America to improve prevention of avoidable epidemics, including naturally occurring outbreaks and intentional or accidental releases of dangerous pathogens; improve ability to detect threats early; and respond rapidly and effectively to public health threats of international concern. The project is being implemented by a Jhpiego-led consortium that includes the Johns Hopkins Center for Health Security, the Johns Hopkins University Applied Physics Laboratory, Global Scientific Solutions for Health, and Johns Hopkins University Center for Global Health.

With funding from Gavi, the Vaccine Alliance, Jhpiego is working in Pakistan on a national introduction of a human papillomavirus (HPV) vaccine. With the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health as a partner, Jhpiego is providing technical assistance to: 1) draft a road map for preparing Pakistan to consider HPV vaccine introduction, 2) bridge gaps in knowledge and understanding of cervical cancer prevention and control, 3) make the investment case for bundling of services to address health for every woman and girl, and 4) support country partners, an HPV working group and HPV champions by providing a secretarial and administrative platform for engagement activities.

With funding from the United Nations Population Fund, Jhpiego is supporting the roll out of postpartum family planning (PPFP) strategies in two provinces in Pakistan. Under this award, Jhpiego will: 1) support government endorsement process for national level PPFP strategy; 2) build the capacity of service providers on PPFP and strengthen selected training sites to provide PPFP services; and 3) assess the establishment of midwifery-led units in hospitals supporting clinical rotations for midwifery students.

This 39-month project, funded by the Bill & Melinda Gates Foundation, pairs an implementation science approach with robust advocacy and coordination to introduce, roll out and scale up use of depot medroxyprogesterone acetate (DMPA-SC) and self-injection. The project provides an opportunity to catalyze change toward the vision for women in Family Planning 2020 countries to have the autonomy and be empowered to make and act on their family planning decisions through expanded choice and access to contraceptive products. Under this award, Jhpiego is conducting implementation research in two districts of Punjab to: 1) learn how best to introduce DMPA-SC and self-injection into a specific market to expand contraceptive options available to women and girls, taking into account health system characteristics as well as women and girls’ needs, interest in self-injection and ability to start and continue use; and 2) understand the demand for self-injection when DMPA-SC is offered alongside a range of other methods.